Home Featured Page 236

Featured

Latest

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

ATMA Journey Centers Offer Regulated Health Care Professionals a Means to...

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey...

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Meet Microdosing TikTok—And Why the Community Matters

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

Bright Minds Biosciences Provides Scientific Update

Psychedelics: Past, Present, Future – Webinar

Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent...

Are Prodrugs the Next Wave of Psychedelic Drug Development?

Small Pharma Successfully Completes Phase I Clinical Trial of DMT in...

EDITOR PICKS

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

ATMA Journey Centers Offer Regulated Health Care Professionals a Means to...

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey...

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Meet Microdosing TikTok—And Why the Community Matters

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

Bright Minds Biosciences Provides Scientific Update

Psychedelics: Past, Present, Future – Webinar

Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent...

Are Prodrugs the Next Wave of Psychedelic Drug Development?

Small Pharma Successfully Completes Phase I Clinical Trial of DMT in...

EDITOR PICKS

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY